Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in Heifei, Anhui province, has reportedly secured RMB150 million (USD21 million) in the first closing of its Series B financing round. The funding was led by Guangzhou Industry Investment, with significant contributions from China Resources International, Guangzhou Guoju Venture Capital, Hefei High Tech Venture Capital, and existing investor Legend Capital.
Focus on iPSC Therapies and Pipeline Development
Nuwacell is focused on developing therapies in the areas of anti-inflammatory repair, tumor immunity, and regenerative medicine. The company boasts two iPSC-derived therapies: mesenchymal-like cell (iMSC) therapy and natural killer cell (iNK) therapy, both of which have received tacit approval for trials in China. These therapies showcase Nuwacell’s commitment to leveraging the potential of iPSC technology to address significant unmet medical needs.
Future Development Plans
Moving forward, Nuwacell plans to expand its pipeline to include iPSC-derived cell therapies targeting Parkinson’s disease and diabetes. This strategic expansion underscores the company’s ambition to become a leader in the field of regenerative medicine and to provide innovative treatment options for patients suffering from these debilitating conditions.-Fineline Info & Tech
